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Despite significant improvements in patient survival and local
disease control, 25% of patients with osteosarcoma develop
metastases and the surgery for many extremity lesions still
includes amputation. Thus, modalities that inhibit tumour growth
and the metastatic cascade will have a significant impact on
patient survival and potential for limb sparing surgery. 
Tumours induce bone destruction by cellular processes, such as
osteoclast-mediated bone lysis. The importance of osteoclast-
mediated lysis has been demonstrated in other malignancies,
where the development of osseous metastases has been shown to
be mediated by soluble tumour-related osteoclast activating
factors (Galasko, 1976). More recently, the induction of specific
osteoclast recruiting factors in osteoblasts/stromal cells following
contact with myeloma and breast cancer cells has been demon-
strated (Chikatsu et al, 2000). Bisphosphonates have recognized
efficacy in reducing bone destruction, pain and pathological frac-
ture in a variety of lytic primary and metastatic diseases of the
skeleton (Thiébaud et al, 1991; Coleman and Purohit, 1993;
Shipman et al, 1997; Bloomfield, 1998; Diel et al, 1998). They
have more recently been shown to inhibit establishment and
growth of prostate cancer metastases, which are generally consid-
ered to be osteoblastic in their growth pattern (Adami, 1997). We
proposed that, as with the intraosseous growth of prostate cancer,
the local spread of osteosarcoma involves proteolytic and osteo-
clast-mediated bone destruction. The bisphosphonates may reduce
bone destruction by uncoupling close regulation of osteoclast
activity by osteoblast-like cells. 
The aims of our study were to examine the effects on the regula-
tion of proliferation and apoptosis by bisphosphonate treatment of
a clonal osteosarcoma cell line. Further, we assessed the expres-
sion of an osteoclast differentiating factor, receptor activator of
NF-kb (RANKL) (Yasuda et al, 1998b) and an osteoclastogenesis
inhibitory factor, osteoprotegerin (OPG) (Simonet et al, 1997;
Yasuda et al, 1998a). Finally, we investigated the effects on
osteoblast-related gene expression by an aminobisphosphonate
and a non-aminobisphosphonate. The use of a bisphosphonate
from each group allows comparison of their relative potencies
with the known effects on osteoclasts and bone resorption studies
(Fleisch, 1993). 
MATERIALS AND METHODS 
Cell culture 
UMR 106-01 cells derived from a 32P-induced osteosarcoma in
rats (Martin et al, 1976) were used. Cells were cultured in 75 cm2
tissue culture flasks (Greiner Cellstar) in a-modified Minimal
Essential Medium (a-MEM) containing hepes 4 g l21, sodium
bicarbonate 1.95 g  621, gentamicin 80 mg  621, pH 7.4 and 10%
fetal bovine serum (FBS), incubated at 37˚C and equilibrated in
5% CO2 in air. Subcultures were performed using 0.0125% trypsin
in 0.5 mM Na2EDTA in calcium and magnesium-free phosphate
buffer (1 3 versene) to harvest the cells. 
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The aminobisphosphonate pamidronate (Aredia, Novartis
Pharmaceuticals, Australia) and non-aminobisphosphonate
clodronate (provided by Prof TJ Martin of St Vincent’s Institute of
Medical Research) were dissolved in sterile water and stored
frozen in aliquots of 1026 M to 1022 M until use. 
Proliferation studies 
Cell count / proliferation studies were performed on UMR 106-01
cells grown in monolayer in 6-well culture plates (10.06 cm2 Nunc
Products), with a plating density of 1000–1500 cells per well in 
a-MEM medium containing 10% FBS. Trypan blue was used to
confirm that only cell populations with greater than 90% cell
viability were used for seeding. Medium was replaced after 1 day
with a-MEM containing 2% FBS for a further 24 hours prior to
treatment of bisphosphonates, at concentrations of pamidronate
1028 to 1024M and clodronate 1026 to 1022M. Medium was
replaced every 48 hours and bisphosphonates replenished with the
new media, to ensure continual exposure of cells to a relatively
uniform concentration of the bisphosphonates. Cells were
harvested at various time points with 0.0125% trypsin in 1 3
versene and were counted on a coulter counter (Model DN,
Coulter Electronics, Bedfordshire, England). Experiments were
repeated at least 3 times with 6 wells per treatment group within
each experiment. Three separate coulter counts were performed on
each well sample and the results compared against controls using
Student’s t-test. 
Apoptosis assessment 
Apoptotic cell ratios in cell cultures were determined by ELISA
quantification of DNA fragmentation (Boehringer Mannheim)
according to the manufacturer’s specifications. Within microtitre
wells, 1 3 104 cells were incubated for 4 hours with serial concen-
trations of the two bisphosphonates. After centrifugation (to
ensure detached apoptotic cells were retained) the cells were lysed
and an aliquot of the supernatant transferred to streptavidin-coated
ELISA microtitre wells and exposed to anti-histone biotin and
anti-DNA POD solutions for 2 hours. Unbound antibodies were
removed by washing and the fragmented DNA-POD immunocom-
plexes were detected photometrically, using ABTS (2,2¢-Azino-
di[3-ethylbenzthiazolin-sulphonate]) substrate. A microtitre plate
reader (Titertek, Multiskan® Plus) was used to record the resultant
color change (at 405 nm against substrate solution as a blank,
wavelength 490 nm) and differences assessed using 1-way
ANOVA and Fisher’s PLSD analyses. 
To confirm the ELISA findings, cultures were assessed for the
characteristic morphological features of apoptosis. Cell cultures
were grown in monolayer on 8 well chamber slides (Lab-Tek, Nunc
Products) and exposed after 24 hours to the two bisphosphonates
for 24 and 48 hours. As with the ELISA studies, slides were briefly
centrifuged on microtitre plate carriers to return detached cells to
the monolayer and the slides were fixed in 3% (v/v) acetic acid in
95% methanol for 1 minute before staining with haematoxylin and
eosin. Three representative high-powered fields (400 3) were
analysed for the percentage of cells exhibiting apoptotic character-
istics of nuclear pyknosis, apoptotic bodies, membrane blebbing
and cytoplasmic inclusions. Results were recorded as an apoptotic
subpopulation of less than 5%, 5 to 20%, or greater than 20%. 
Genotype studies 
UMR 106-01 cells were seeded at 1 3 104 cells per 56 cm2 plate
(Falcon, Becton Dickinson) in a-MEM containing 10% FBS.
Medium was replaced after 24 hours with a-MEM containing 2%
FBS to reduce effects of endogenous cytokines on cell growth.
Bisphosphonate treatment was not started until 24 hours after this
change and media and bisphosphonates ware replenished every
48 hours. Bisphosphonate was added at concentrations of between
1 3 1028 and 1 3 1024 M for pamidronate and 1 3 1026 and 1 3
1022 M for clodronate over time frames of between 6 days and
4 hours, prior to confluence of control cultures. Previous experi-
ments on the UMR 106-01 cells line allowed characterization of
the culture growth pattern and accurate prediction of times to
control cell culture confluence. All times and concentrations were
assessed in triplicate. 
Total RNA was isolated from the UMR 106-01 cultures using
TRIZOL (Gibco PRL, Life Technologies) according to the manu-
facturer’s instructions and redissolved in RNase-free TE Buffer,
pH 8.0, to a concentration of 2 mg ml21 and stored at – 80˚C. As
total RNA from each culture was diluted to a standard 2 mg ml21,
prior to agarose gel electophoresis, the resultant Northern
hybridization studies allow comparative analysis of mRNA as a
percentage of total RNA in each treatment group. 
Synthesis of riboprobes 
Probes were labelled with digoxigenin (DIG) using an RNA
labeling kit (Boehringer Mannheim GmbH, Mannheim, Germany)
according to the manufacturer’s instructions. 
A 2.4 kb EcoRI fragment of rat alkaline phosphatase (ALP)
cDNA, Dr. G. Rodan, Merck, Sharp and Dohme Research
Laboratories, West Point, PA, was further cut with BamH1 and the
1.1 kb  EcoR1-BamH1 fragment was subcloned into Stratagene
pBluescript plasmid (pBS). The plasmid was linearized with
BamHI and transcribed with T7 RNA polymerase to generate a
1.1-kb antisense riboprobe. A 500 bp EcoRI fragment of rat bone
GLA protein/osteocalcin (BGP) cDNA (Dr J Wozney, Genetics
Institute, Cambridge, MA) was subcloned into pBS plasmid vector
and then linearized with HindIII before being transcribed into the
antisense strand with T3 RNA polymerase. Rat matrix GLA
protein (MGP) cDNA (Dr P Price, University of San Diego, La
Jolla, CA) was subcloned into pBS. The plasmid was linearized
with HindIII and transcribed with T3 to produce an antisense ribo-
probe. A 1.6 kb XbaI-XhoI insert of human osteopontin (OPN)
cDNA in pBS (Dr L Fisher, National Institute of Dental Research,
USA) was linearized with XbaI and transcribed with T7 poly-
merase to generate the antisense riboprobe. Pro-a1(I) collagen
RNA riboprobe was obtained by subcloning a 1.6 kb Pst I frag-
ment of rat pro-a1(I) collagen cDNA (Dr J Bateman, Royal
Children’s Hospital, Melbourne, Australia) into the pSPT 19. This
plasmid vector was linearized using EcoRI and was then tran-
scribed with T7 RNA polymerase to generate a 1.6 kb antisense
riboprobe. A 750 bp RANKL cDNA fragment, (bp 381–1130)
(Wong et al, 1997) and a 545 bp OPG cDNA fragment (bp
778–1323) (Simonet et al, 1997) were obtained from N Horwood
and R Thomas, St Vincent’s Institute of Medical Research,
Melbourne, Australia. Each reverse transcription polymerase
chain reaction product was cloned into pGEM-T, linearized with
NdeI and transcribed with T7 RNA polymerase to generate the
respective antisense riboprobes (Kartsogiannis et al, 1999). 
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Total RNA was loaded at 20 mg per lane and separated overnight in
a 1.5% agarose-formaldehyde gel. The RNA was transferred by
vacuum suction to nylon hybridization filters (Genescreen, NEN
Life Science Products) hybridized overnight in a buffer solution
(formamide 50%, 5 3 SSC, block reagent 2% (Boehringer
Mannheim), SDS 0.02%) with DIG labeled riboprobes at a
concentration of 25 ng ml21. Probes for OPN, ALP, Pro-a1 (I)
collagen, BGP, MGP, RANKL and OPG were used. Sequential
washes (2 3 SSC / 0.1% SDS, 2 washes of 5 minutes at room
temperature, 2 washes at 65˚C in 0.1 3 SSC / 0.1% SDS). The
hybridized probes were subsequently detected with anti-DIG anti-
body coupled to alkaline phosphatase (Boehringer Mannheim) and
visualized by chemiluminescence autoradiographic detection with
CDP-Star (Boehringer Mannheim). 
Filters were stripped of probe by washing in DEPC-treated H2O
followed by 15 minutes washing in 50% formamide, 50 nM Tris-
HCl (pH8.0) and 1% SDS at 100˚C, and stored in 2 3 SSC.
Hybridized probes were normalized against a DIG-labelled 18 S
oligonucleotide probe (amino acid (180–156) sequence: CGG
CAT GTA TTA GCT CTA GAA TTA CCA CAG) (Chan et al,
1984) and detected with Anti-DIG as described above. 
mRNA was quantitated by densitometry (ImageQuaNT soft-
ware, Molecular Dynamics), normalizing each probe expression
against 18 S expression on the same filter, and repeated with at
least 3 filters for each probe. 
RESULTS 
Cell proliferation and cell death study 
There was a dose-related inhibition of cellular proliferation of
UMR 106–01 cells in monolayer culture with both bisphosphon-
ates used. At 1 3 1024 M pamidronate exposure and > 1 3 1022 M
clodronate exposure marked cytotoxicity was noted, with death of
all cells within 24 to 48 hours (results not shown). Inhibition of
growth occurred at concentrations of pamidronate between 1 3
1026 M and 1 3 1025 M and clodronate between 1 3 1022 M and 1
3 1022 M (Figures 1A, 1B). 
DNA internucleosomal fragmentation, detected by ELISA
utilizing anti-DNA and anti-histone antibodies, increased more
than 3-fold in cell cultures exposed for 4 hours to 1024 M
pamidronate (Figures 2A, 2B). Fragmentation at pamidronate
concentrations of 1025 M to 1029 M and with clodronate concen-
trations of 1023 M and 1025 M was greater than in control cultures
(P < 0.05). Using 1-way ANOVA analysis no statistical dose-
dependent difference was noted between the concentrations
studied within each treatment group. 
Examination of cells treated at 1 3 1025 to 1 3 1024 M of
pamidronate by phase contrast microscopy demonstrated large
numbers of non-viable cells within the cultures. Large numbers of
cells were seen exhibiting intracytoplasmic inclusions, loss of cell
shape, loss of cell to cell and cell to surface adhesion, and the pres-
ence of apoptotic bodies (Figures 3A, 3B). Visual quantification of
the percentage of cells exhibiting these features demonstrated an
increase in the proportion of apoptotic cells in cultures exposed to
higher bisphosphonate concentrations (Table 1). Exposure
to clodronate at doses approximately 100-fold higher than those of
pamidronate produced similar morphological features of apoptosis
within the osteosarcoma cultures. These features of cytotoxicity
were not thought to be due to the calcium-chelating effect of
bisphosphonates, as cultures exposed to equimolar concentrations
of EDTA did not produce the same effect (results not shown). 
Gene expression 
At 1 3 1025 M pamidronate the expression of OPG was unaltered
over treatment periods of 0 to 5 days when normalized against
18 S expression on the same filter. RANKL mRNA expression
was down regulated by prolonged exposure of the cells to
pamidronate, when normalized against 18 S and hybridizing equal
amounts of total sample RNA compared with control RNA
(Figure 4A, 4B). 
There was a significant reduction in OPN mRNA expression,
again when normalized against 18 S on the same filters and
compared with equal control total RNA hybridization. We noted
no change in the expression of ALP or pro-a1 (I) collagen
mRNA (Figures 4A, 4C). Similar effects on mRNA expression
for the above proteins were observed in cells treated with
clodronate, albeit at a concentration 100-fold that of
pamidronate (results not shown). BGP and MGP are expressed
in some osteoblast-like cell lines however there is no inherent
expression of mRNA for these matrix proteins by UMR106-01
cells and exposure to bisphosphonate did not alter this.
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Figure 1 The effect of bisphosphonate exposure on proliferation of UMR
106–01 cells grown in monolayer. Cells were detached by trypsinization and
counted by coulter counter on the days indicated. Points are mean of three
samples. Experiments were performed more than three times with similar
results and low standard error of means (not discernible at this resolution). 
(A) – Pamidronate exposure. 1028 M to 1025 M. (B) – Clodronate exposure.
1026 M to 1022 M. (*) = P-value < 0.05 compared against control Exposure of the cultures to concentrations of pamidronate <
1025 M and clodronate <1023 M did not significantly alter
mRNA expression, as detected by Northern hybridization
(results not shown). 
DISCUSSION 
To study the effects of bisphosphonates on osteosarcoma cells in
vitro we have utilized the UMR 106-01 cell line. This cell line is
very well characterized and has been used, in our laboratory, to
induce reproducible and representative tibial osteosarcomas in
nude mice (unpublished). We have shown that pamidronate and
clodronate have a dose- and time-dependent inhibitory effect on
monolayer growth of osteosarcoma cell. Studies on the effect of
bisphosphonates on osteoblasts have differed in their findings
although several have demonstrated inhibitory effects at higher
doses (Evans and Braidman, 1994; Goziotis et al, 1995; García
Moreno et al, 1998). Plotkin et al showed that bisphosphonates
prevent osteoblast apoptosis using several criteria, however noted
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Figure 2 Assessment of apoptosis after 4 hours of bisphosphonate
exposure to 1 3 104 UMR 106–01 cells. The apoptotic subpopulation was
detected by ELISA photometric assay (405 nm against substrate solution
approx 490 nm) and the enrichment factor for apoptosis compared with
untreated cells graphically shown. Error bars represent SE mean over three
experiments. 2(A) – Pamidronate exposure 1029, 1027, 102 5, 1024 M. 2(B) –
Clodronate exposure 1027, 1025, 102 3 M. (*) = P-value < 0.05 compared
against control. 
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Figure 3 Representative microphotographs of UMR 106–01 cells grown in
monolayer, fixed with acetic acid 3% v.v. in methanol and stained with
hematoxylin and cosin. (A) – Untreated cells with distinct cellular structure
and frequent mitoses (arrow heads) 3 400 (B) – Following 24 hours of
pamidronate (1025 M) apoptotic cells are more frequent, with many apoptotic
bodies developing from nuclear fragmentation (arrows) 3 400 
24 Hours <5%
48 Hours <5%
Control Pamidronate Clodronate
10-9 M1 0
-7 M1 0
-5 M1 0
-7 M1 0
-5 M1 0
-3 M
< 5% < 5%
< 5% < 5% < 5%
< 5% < 5% < 5%
< 20% 5-5%
5-20%
5-20%
Table 1 Morphological assessment of apoptotic cells in monolayer on 8 well tissue culture microscopy slides. Three representative high-power fields were
examined and the number of cells exhibiting characteristic features of apoptosis determined as a percentage of the total population. (<5% of cells apoptotic. 
5–20 % of cells apoptotic. >20% of cells apoptotica biphasic response, and were unable to resolve an increase in
morphological signs of apoptosis seen in osteocytes exposed to
bisphosphonates (Plotkin et al, 1999). An inhibitory effect was
noted by Tan et al in 3H-thymidine uptake studies in UMR 106
osteosarcoma cells exposed to pamidronate (Tan et al, 1988),
although the effect on cellular metabolic activity (rather than cell
number) at 5 3 1024 M was assessed. Time-or concentration-
dependent differences were not reported. 
As observed in our study, pamidronate exposure of >1024 M
was cytotoxic to the cell monolayer whereas at 1 3 1025 M
pamidronate we noted an inhibition of proliferation and an
increase in the proportion of cells in monolayer undergoing
apoptosis. At this lower concentration we demonstrated no
change over time in the expression of ALP or pro-a1 (I) collagen
mRNA but there was progressive down regulation of OPN and
RANKL mRNA expression. This selective alteration in mRNA
expression suggests that pamidronate, at a dose of 1 3 1025 M,
may regulate specific cell functions, such as proliferation and
gene expression rather than inducing direct cytotoxicity. The
dose at which effects on the osteosarcoma cell line were noted is
higher than those used in many studies on osteoclasts, although
similar concentrations have been demonstrated to cause apop-
tosis in breast cancer cell lines (pamidronate >1 3 1025 M)
(Senaratne et al, 2000) and myeloma cell line cultures
(pamidronate >1 3 1024 M) (Shipman et al, 1997). These find-
ings may still be significant if translated to the in vivo setting, as
the strong hydroxyapatite affinity of bisphosphonates is thought
to drive their local concentration within the bone microenviron-
ment significantly higher than the serum level. Novel studies by
Sato et al demonstrated localization of radiolabelled alendronate
beneath resorption lacuna at concentrations approaching 1 3
1023 M (Sato et al, 1991) and further in vitro assays demon-
strated an inhibitory IC50 of 1026–1025 M for pamidronate in an
ivory slice assay of osteoclast activity. 
We have studied the effects of bisphosphonates on the expres-
sion of two factors by an osteosarcoma cell line which are known
to be physiological regulators of osteoclast activity. The osteoclast
differentiating factor (RANKL) (Yasuda et al, 1998b) and M-CSF
(Yoshida et al, 1990) are required for osteoclast differentiation.
Regulation of these two factors is thought to be the common final
pathway by which the resorption-inducing agents such as parathy-
roid hormone, 1,25 dihydroxyvitamin D3 and interleukins promote
osteoclastogenesis (Horwood et al, 1998). The soluble TNF family
member (OPG) acts as a decoy receptor for RANKL, and expres-
sion by osteoblasts under hormone regulation is thought to inhibit
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Figure 4(A) Detection of mRNA expression for bone-related proteins and
osteoclast-regulating factors. UMR 106–01 osteosarcoma cell monolayer
cultures were exposed to 1025 M pamidronate for 1 to 6 days prior to
confluence of controls. Total RNA (20 mg) was loaded in each lane, separated
by gel electrophoresis and mRNA visualized as described in the text. 18S
ribosomal detection was performed to normalize the amount of RNA present
in each lane. Numbers above each lane represent number of days of
pamidronate exposure. Control = untreated cells. OPN = osteopontin:
RANKL = receptor activator of NF-kB ligand: ALP = alkaline phosphatase:
Col = pro-a1(1) collagen: OPG = osteoprotegerin: 18 S = Housekeeping gene 
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Figure 4 (B and C) Densitometric analysis of Northern hybridization for
bone-related factors and osteoclast regulating genes. Filters with bound and
visualized mRNA probes were analysed and normalized against the
corresponding 18 S control bands for each filter. Y-axis represents the value
expressed as a ratio of the normalized untreated control for the same time
point and concentration. Average and range of three filters shown for each
probe. (B) OPG = osteoprotegerin. RANKL = receptor activator of NF-kB
ligand (C) ALP = alkaline phosphatase. Col = pro- a1(1) collagen. OPN =
osteopontin osteoclastogenesis by binding the differentiating factor (Simonet
et al, 1997; Yasuda et al, 1998a). 
We found that OPG mRNA expression was unaltered by the
bisphosphonates and RANKL expression was reduced. This
down-regulation of RANKL mRNA expression suggests that
interference with osteoclastogenesis by the bisphosphonates could
be, in part, attributable to inhibition of the release of osteoclast
differentiating factors by stromal cells or osteoblasts. It has
recently been shown that the induction of osteoclastogenesis is
dependent upon the relative abundance of RANKL compared with
the levels of OPG (Horwood et al, 1998). The anticipated in vivo
net effect of RANKL down-regulation but with stable OPG levels
would be a reduction in local osteoclast recruitment or activation
(Figure 5). The expression of mRNA for RANKL by osteosar-
coma cells in vitro raises the possibility that the tumours may
directly recruit osteoclasts at the tumour-bone interface in vivo,
rather than acting on host stromal cells to induce osteoclast recruit-
ment (as seen in metastatic skeletal malignancies). Alteration in
the ratio of osteoclast recruiting and inhibiting factors following
bisphosphonate exposure suggests these agents may have an effect
on this paracrine recruitment. 
Bisphosphonates exert their anti-resorptive effects via several
mechanisms. They are known to be internalized and induce osteo-
clast apoptosis following resorption of bisphosphonate-coated bone
(Flanagan and Chambers, 1989) while other studies have identified
apoptosis of osteoclasts directly exposed to bisphosphonates. Vitté
and colleagues (Vitté et al, 1996) and Sahni et al (1993) hypothe-
sized that bisphosphonates affect osteoclast differentiation, survival
and activity via osteoblast-produced intermediaries but did not
identify these compounds. Yu et al subsequently demonstrated that
UMR 106 cells express an osteoclast-inhibiting factor following
bisphosphonate exposure and an osteoclast-stimulating factor after
parathyroid hormone exposure (Yu et al, 1996). This supports the
possibility that an imbalance in the relative expression of the osteo-
clast regulating genes by UMR 106 following bisphosphonate
exposure might be responsible for the functional osteoclast impair-
ment. This has important implications on our hypothesis that osteo-
clast-mediated tumour spread occurs in the local growth of
osteosarcoma, and suggests the bisphosphonates may have an
inhibitory effect on such growth in the in vivo setting. 
DNA internucleosomal fragmentation, which is identified by
a variety of commercial apoptosis assays, is an early event in
apoptotic cell death (Arends et al, 1990). In this study we have
demonstrated a significant increase in apoptosis in bisphosphonate-
exposed cultures, but have not demonstrated a significant concen-
tration-dependent effect with either bisphosphonate, following
4 hours of exposure. Although an increase is noted at 1024 M
pamidronate exposure, this concentration clearly caused marked
cytotoxicity and had been previously excluded from proliferation
and mRNA analyses. Despite no statistically significant dose-
dependent changes in apoptosis in the first hours of bisphospho-
nate exposure our observation of increased apoptotic ratios on
morphological assessment at 24 to 48 hours within the UMR 106-
01 osteosarcoma cell cultures suggests ongoing effects. 
During this early period of bisphosphonate exposure metabolic
changes may be occurring within the cells which later direct the
cell towards programmed cell death. Jilka et al demonstrated that a
calvarial osteoblast culture and an osteosarcoma cell line culture
exhibit background apoptosis, which may be modulated by
various agents known to be involved in the regulation of Bone
Modeling Units (BMUs) (Jilka et al, 1998). They were able to
correlate this with TUNEL stain confirmation that a subpopulation
of up to 50–70% of osteoblasts within BMUs may be lost to apop-
tosis. The mechanism by which bisphosphonates may induce
osteoblast apoptosis and the relative potency or effect on osteosar-
coma cells in vivo requires further investigation. The pathways by
which the non-amino and aminobisphosphonates induce apoptosis
in osteoclasts, breast cancer cells and macrophages are currently
being studied and already the two broad groups of bisphospho-
nates have been found to differ in their mode of action (Luckman
et al, 1998). The inhibitory effects of the amino-bisphosphonates
on the mevalonate pathway in osteoclasts has now been well
described (Russell et al, 1999; Rogers et al, 2000). However, the
differing mode of action of clodronate (as described in osteoclasts)
suggests that the effects we have noted on the osteosarcoma cells
exposed to both clodronate and an amino-bisphosphonate are not
attributable to an effect on the mevalonate pathway. 
We have demonstrated a bisphosphonate-mediated down-
regulation of OPN mRNA expression in an osteosarcoma cell line.
OPN has been shown to mediate cell attachment and migration of
malignant cells in culture (Oldberg et al, 1986; Majeska et al,
1993). It also has a well-defined role in protein mediated adher-
ence between osteoblasts and the extracellular bone matrix
(Butler, 1989; Helfrich et al, 1992; Majeska et al, 1993; Ross et al,
1993). The inhibition of OPN expression in osteoblasts by bispho-
sphonates has been reported by Sodek et al in mixed cultures of
calvarial cell (Sodek et al, 1995). They demonstrated a reduction
of OPN mRNA expression of approximately 50%, and to a much
lesser degree reduced expression of type 1 collagen mRNA, but no
alteration in the mRNA expression of bone sialoprotein and osteo-
calcin (Bone GLA protein). Osteoclasts and numerous non-bone
tissues also express OPN (Denhardt and Guo, 1993; Merry et al,
1993; Dodds et al, 1995) and a role for OPN in cell to matrix
binding has also been proposed in these cells (Reinholt et al,
1990). Recently, the importance of OPN for bone resorption in
vivo has been demonstrated. Significantly less osteoclastic activity
occurred on OPN-deficient bone discs implanted into the muscle
of OPN knockout mice when compared to wild-type controls.
Osteoclast activity was rescued by addition of recombinant OPN
to the bone discs (Asou et al, 1999). These in vivo studies support
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Figure 5 Mechanisms via which the bisphosphonates may affect osteoclast
function. Downregulation of RANKL mRNA expression in the presence of
continued OPG mRNA production accounts for a net reduction in osteoclast
differentiating signals from osteoblasts as the relatively abundant OPG
saturates RANKL. RANKL binding to the receptor on osteoclast progenitor
cells is thus inhibited. Direct apoptotic effects on mature osteoclasts are
known and differentiation of osteoclasts is also thought to be directly
suppressed.our studies and the proposal of Sodek et al that the OPN down-
regulation in osteoblasts exposed to bisphosphonates may impair
OPN-regulated osteoclastic bone resorption (Sodek et al, 1995). 
Up-regulation of the OPN gene is found in primary metastatic
tumours of various origins (Brown et al, 1994). Such up-regulation
has been proposed to be a factor in tumorigenicity, possibly medi-
ating tumour cell attachment to host tissues (Behrend et al, 1994,
1995; Gardner et al, 1994). It is known that transformed cell lines
express higher levels of OPN than normal cells, although the
significance of such expression remains unclear (Craig et al,
1988). Studies are required to demonstrate whether OPN inhibi-
tion observed in our study is mirrored in the primary tumours of in
vivo models of osteosarcoma, and whether such inhibition is asso-
ciated with an alteration in the biological activity of the tumour.
The inhibition by nitrogen-containing bisphosphonates of breast
cancer cell attachment to bone matrix in vitro (van der Pluijm et al,
1996; Boissier et al, 1997) bears out the role of these agents in
reducing the bone metastatic burden of breast and prostate cancer
now seen clinically. It has been suggested that the inhibiting effect
of bisphosphonates on OPN expression in metastatic sub-clones of
breast cancer may, in part, account for the reduction in metastatic
disease (Orr et al, 1995). 
We have demonstrated an inhibitory effect of bisphosphonates
on cell proliferation as well as the expression of differentiated
osteoblast function in a clonal rodent osteosarcoma cell line.
Furthermore we have demonstrated an alteration in mRNA expres-
sion for OPN and RANKL, which may produce a net reduction in
osteoclast function. If such osteoclast activity, or the phenotype of
osteosarcomas, is altered by bisphosphonate exposure this may
have specific implications in the advancement of osteosarcoma
management. Future studies may be able to further elucidate the
mechanisms by which the mRNA signal is regulated by the
bisphosphonates and to ascertain whether post-transcriptional
control of mRNA expression, or subsequent protein expression, is
altered by bisphosphonates exposure. Additional studies are required
to determine if such bisphosphonate effects are translated into the in
vivo setting to functionally alter tumour-related osteoclast activity. 
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